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1. Introduction 
Glucocorticoids (GCs), steroid hormones produced predominantly by the adrenal gland, are 
key mediators of stress responses. Whilst the acute and chronic effects of pharmacological 
glucocorticoid excess are well-recognized (including induction of hyperglycemia, insulin 
resistance, hyperlipidemia, hypertension and dysphoria, with suppression of immune, 
inflammatory and cognitive processes), their role in the biology of the response to stress is 
more nuanced, with balanced homeostatic effects to facilitate short-term survival and 
recovery from challenge [1, 2]. In addition, glucocorticoids play an essential role in normal 
fetal development and are important for the development and maturation of various fetal 
tissues including the liver, lungs, gut, skeletal muscle and adipose tissue in preparation for 
extrauterine life. Glucocorticoids most notably act during late gestation to stimulate 
surfactant production by the lung. This action is critical to prepare the fetus for extrauterine 
life, and it is for this reason that synthetic glucocorticoid treatment is so widely used in 
preterm pregnancies where lung immaturity threatens neonatal viability. Although these 
treatments greatly improve survival [3], they are not without adverse effects.  
Glucocorticoids regulate many of the processes required for successful embryo 
implantation, as well as for the subsequent growth and development of the fetus and 
placenta. In utero, the endometrium, placenta and embryo/fetus are each exposed to 
physiological glucocorticoids arising from either maternal or fetal adrenal glands. It has 
been shown that glucocorticoids have several roles in improving the intrauterine 
environment. For example, in uterus, glucocorticoids regulate the synthesis of 
prostaglandins that have been implicated to play critical roles during implantation by 
increasing stromal vascular permeability [4] and in the initiation of parturition [5]. The peri-
implantation secretion of human chorionic gonadotrophin (hCG) from human term 
trophoblasts can be stimulated by up to 10-fold by treatment for 24 to 72 h with synthetic 
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glucocorticoids dexamethasone and triamcinolone [6, 7]. Glucocorticoids have several anti-
inflammatory actions required for implantation. In first trimester human cytotrophoblasts, 
cortisol can suppress the synthesis of the pro-inflammatory interleukin (IL)-1b [8]. Similarly, 
in term human placental cytotrophoblasts, physiological concentrations of cortisol and 
numerous synthetic glucocorticoids can inhibit secretion of pro-inflammatory cytokines 
tumor necrosis factor (TNF)-α, IL-6 and IL-8 without affecting the expression of anti-
inflammatory cytokine IL-10 [9-11]. Glucocorticoids contribute to preventing immunological 
rejection of the fetal semiallograft in the pregnant uterus by inhibiting eosinophil infiltration 
[12]. Moreover, glucocorticoids profoundly and specifically suppress expression of 
fibronectin and laminin, two extracellular matrix proteins that are important mediators of 
uterine–placental adherence [6]. 
Furthermore, glucocorticoids activate many of the biochemical processes in these tissues 
such as altering expression of numerous receptors, enzymes, ion channels, transporters, 
growth factors, cytoskeleton proteins, binding proteins, clotting factors, gap and tight 
junction proteins and intracellular signaling pathways’ components involved in growth. 
Taken together, these glucocorticoid-induced changes in cell physiology combine to 
produce functional alterations at the systemic level [13]. 
In pregnancy, glucocorticoid administration is used mainly in the management of women 
at risk of preterm labor and in the antenatal treatment of fetuses at risk of congenital 
adrenal hyperplasia. It is recommended that, for pregnant women who are at risk of 
preterm delivery within 7 days between 24 weeks and 34 weeks of gestation, a single 
course of corticosteroid administration should be performed. And a single course of  
antenatal corticoids should be administered to women with premature rupture of 
membranes before 32 weeks gestation to reduce the risks of respiratory distress syndrome, 
perinatal mortality and other morbidities [14]. Numerous evidence indicates that increased 
exposure of the fetus to glucocorticoids in mid- to late pregnancy may result in adverse 
outcomes including intrauterine growth restriction (IUGR) [15-18], postnatal hypertension 
[15, 19], postnatal cardiovascular disease [20], postnatal glucose intolerance [20], increased 
postnatal activity in the hypothalamo–pituitary–adrenal axis [21-24], effects on fetal brain 
development [21, 25, 26].  
Glucocorticoid actions within the cell are regulated by Glucocorticoid Receptor (GR) [27]. 
On hormone binding, activated GR translocates from the cytoplasm to the nucleus as a 
dimer to associate with specific DNA sequences termed glucocorticoid response elements 
(GREs) and acts as a ligand-dependent transcription factor [28]. GR-mediated 
transcriptional activation is modulated by phosphorylation [29]. GRs are highly expressed in 
decidua, chorion, amnion, stromal fibroblasts, vascular smooth muscle cells and endothelial 
cells of human term placentas, with moderate expression in cytotrophoblasts and negligible 
expression in syncytiotrophoblast [30-34]. Because the significance of glucocorticoids to the 
early mammalian embryo is clear and glucocorticoid action within the cell is regulated by 
GR, we investigated GR expression during the course of rat embryogenesis until day 12 of 
gestation. The demonstrated ontogenetic pattern of GR expression indicates the potential 
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sites of biological action of the glucocorticoids, providing supportive evidence for its critical 
importance during the course of embryogenesis in rats [35].  
The intracellular enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD) catalyzes the 
interconversion of bioactive glucocorticoids (cortisol and corticosterone) and their inactive 
metabolites (cortisone and 11-dehydrocorticosterone). Thus, it is an important modulator of 
glucocorticoid  bioavailability  in  both  glucocorticoid  and  mineralocorticoid  target organs  
[36]. To date, two 11β-HSD isoenzymes (known as 11β-HSD1 and 11β-HSD2) have been 
identified, characterized and cloned [37]. The conversion of cortisone to active cortisol is 
catalyzed by 11β-HSD1, whereas the metabolism of cortisol to cortisone is mediated via both 
11β-HSD1 and 11β-HSD2 [38]. In placenta, 11β-HSD1 protein is expressed specifically in the 
placental villous endothelial cells, amnion, chorionic and extravillous trophoblasts (EVTs). 
11β-HSD1 expression increases throughout pregnancy in response to progesterone [39]. As 
the placenta differentiates, there is an up-regulation in the expression of 11β-HSD2 enzyme 
that becomes the major placental isoenzyme [40]. 11β-HSD2 protein is localized exclusively 
in the syncytiotrophoblast and invasive extravillous trophoblasts with no expression in the 
chorion or amnion [41-43]. The distinct pattern of 11β-HSD1 and -2 localizations may 
indicate having different physiological functions. In normal pregnancy, maternal 
glucocorticoid levels are markedly higher than those in the fetal circulation. It has been 
stated that the role of placental 11β-HSD is to protect the fetus from adverse effects of 
maternal glucocorticoids. 11β-HSD2 is better suitable for this role because of its location (the 
site of maternal–fetal exchange) and its enzymatic properties (higher affinity for cortisol). 
This enzyme acts as a ‘barrier’ to prevent premature or inappropriate action at 
glucocorticoid-responsive tissues during fetal development [44]. It has been suggested that a 
reduction in the expression or activity of placental 11β-HSD2, by leading to increased 
transplacental passage of active glucocorticoids, reduces fetal growth. 11β-HSD2 knockout 
(11β-HSD2−/−) mice exhibit reduced birth weight and heightened anxiety in adulthood [45]. 
Numerous studies have shown that inhibition of 11β-HSD2 during pregnancy leads to a 
reduction in birth weight and the development of later hypertension and glucose 
intolerance [46-48], as well as programming increased HPA axis activity and anxiety-related 
behaviors [49]. Moreover, placentas from 11β-HSD2 knockout mice fetuses have impaired 
labyrinth zone capillary development accompanied by a decline in vascular endothelial 
growth factor (VEGF)-A mRNA expression and altered transport of nutrients by system A 
amino acid transporter (SNAT) [50]. Furthermore, a correlation between decreased activity 
of 11β-HSD2 in the human placenta and IUGR has been reported [15, 51, 52]. In addition, 
mutations in the HSD11B2 gene in humans, although rare, markedly reduce birth weight 
[53]. It was found that while maternal administration of glucocorticoids caused IUGR, 
glucocorticoid administration directly into the fetal circulation did not restrict fetal growth, 
which suggests that the growth limiting effects of glucocorticoids are mediated via actions 
in the utero-placental unit rather than effects on fetal tissues [54] 
Placental development is a critical determinant of fetal growth and glucocorticoids affect 
growth and development of the fetus indirectly by affecting placental development and 
function. The actions of glucocorticoids on fetal growth are mediated, in part, by changes in 
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the placenta. In sheep, rats, mice and non-human primates, administration of synthetic 
glucocorticoids during late gestation reduces placental weight. In most of these species, the 
effect of glucocorticoids on the placenta is greater than that on the fetus [13]. Glucocorticoids 
have been implicated in the fusion of cytotrophoblast cells to form the syncytiotrophoblast 
and associated with morphological (accelerated apical microvilli formation, nuclear 
maturation, and increase in cell organelle number) and functional (elevated hCG secretion 
and increased 11β-HSD2 mRNA expression) markers of syncytiotrophoblast differentiation. 
These findings suggest that glucocorticoids stimulate syncytiotrophoblast differentiation 
and maturation [55-57].  
Microarray analysis showed that maternal glucocorticoid administration leads to marked 
changes in the gene expression profile in the placenta. Dexamethasone (Dex) caused a 
decrease in expression of genes involved in cell division such as cyclins A2, B1, D2, CDK 2, 
CDK 4 and M-phase protein kinase along with growth-promoting genes such as epidermal 
growth factor receptor, bone morphogenetic protein 4 and insulin-like growth factor-
binding protein 3. In addition, Dex treatment led to down-regulation of genes involved in 
protein biosynthesis, skeletal development, and collagen metabolism. There was also 
decreased expression of genes involved in cell division, DNA replication, chromosome 
segregation, DNA alkylation, nucleotide and nucleoside biosynthesis, microtubule-based 
processes, B-cell activation and differentiation processes, innate immune response, antigen 
processing and presentation, and complement system [58]. Treatment of rats with 
glucocorticoids restricts placental vascular development via inhibition of the VEGF-A and 
peroxisome proliferator-activated receptor γ (PPARγ) which is regulated by VEGF-A 
expression [59, 60]. In addition, in response to glucocorticoid treatment of either the mother 
or fetus, there are changes in the placental handling of certain amino acids such as 
alanine, glutamine and glutamate. However, there have been few studies on the effects of 
glucocorticoids on amino acid transporters in the placenta of any species to date [61, 62]. 
Additionally, glucocorticoids change the production and metabolism of hormones by the 
placenta such as prostaglandins, placental lactogen, leptin, corticotrophin-releasing 
hormone (CRH), estrogens, progesterone and other progestagens [63, 64]. Glucocorticoids 
also alter the placental activity of various enzymes involved in the synthesis and 
inactivation of steroids and thyroid hormones such as 17,20-lyase, 17α-hydroxylase, 
aromatase, renin and endothelial nitric oxide synthase [63].  
2. The effects of glucocorticoids on placental cell cycle 
Glucocorticoids play a fundamental role in pregnancy with effects on decidualization, 
implantation, placental development, fetal brain development, lung maturation and 
parturition but fetal-placental exposure to maternally administered glucocorticoids may 
lead to abnormalities of fetal and placental growth [15, 19, 65]. The mode of action of 
glucocorticoids in placental growth inhibition has not been determined.  
Human placental development is established by trophoblast invasion into the uterine 
endometrium and its vasculature. The resulting changes will facilitate an increase in 
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intervillous blood flow and, hence, the exchange of nutrients and molecules between 
maternal and fetal blood. The transports as well as metabolic and endocrine functions of 
the placenta reside primarily in the floating villi covered by the syncytiotrophoblast, a 
tissue that results from terminal differentiation of underlying villous cytotrophoblasts 
and their subsequent fusion. Anchoring villi establish physical connection of the placenta 
with the decidua predominantly by a subpopulation of cytotrophoblasts known as EVT. 
They accumulate at the tips of the anchoring villi and form cell columns. Both villous 
and extravillous cytotrophoblast subpopulations arise by proliferation and 
differentiation from stem cells located within the cytotrophoblast layer of the chorionic 
villi [66]. 
On the basis of the immunostaining of the Ki67 antigen, a cell cycle regulator with yet 
unknown role, EVTs have been categorized as the proliferative phenotype, which is 
primarily located in the proximal part, and the invasive phenotype that is located mainly in 
the distal part of cell columns [66]. Current understanding assumes that EVT can 
differentiate, thereby acquiring an invasive phenotype, which eventually enables them to 
invade the maternal decidua and spiral arteries. Thus placental development involves 
proliferation and differentiation of the cytotrophoblasts in a manner that is tightly regulated 
in time and space. 
Eukaryotic cell cycle consists of four phases, G1, S, G2 and M. G1 and G2 are preparation 
phases for DNA synthesis (S) and mitosis (M) phases respectively. During G1 and G2 
phases cell growth, doubling of the amount of protein and organelles and preparation for 
the next phase occurs. If the conditions are not appropriate, cells in G1 phase stop cell cycle 
progression and enter into a resting state, known as G0 phase, where they continue 
biological functions but do not go through the rest of the cell cycle. When growth signals are 
received, cells in G0 phase can continue the cycle through the G1 phase [67, 68]. 
The eukaryotic cell cycle is regulated by the coordinated activity of a family of cyclin-
dependent kinases (CDKs). These are positively and negatively regulated by the cyclin and 
CDK inhibitor families [69, 70]. Based on the timing of their appearance in the cell cycle, 
cyclins can be divided into two groups, i.e. the mitotic cyclins A and B and the G1 cyclins of 
the D and E families [71]. Cyclin A promotes both G1/S and G2/M transitions, whereas 
cyclin B1 accumulates in the cytosol during late S phase and G2 and enters the nucleus at 
the onset of mitosis [72]. 
In mammalian cells, there are at least two distinct families of CDK inhibitors: the INK4 and 
the Cip/Kip inhibitors (p21, p27, p57). Both families play regulatory roles during the G1/S 
cell cycle checkpoint [73]. Because of their broader panel of CDKs with which they interact 
[74], the inhibitors of the Cip/Kip family control other checkpoints as well. p21 plays a role 
during the G2/M phase transition [75] and may also mediate S phase [76] and G2 arrest [77]. 
Overall it is correlated with cell cycle arrest before terminal differentiation [78]. Also, p27 
has the capacity to arrest cells in G2 [77]. p57 inhibits cyclin A- and E-associated CDKs and 
therefore regulates G1/S transition and completion of S phase [79] and is primarily 
expressed in terminally differentiated cells [80]. 
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Despite the importance in understanding the mechanisms controlling proliferation, little is 
known about how cytotrophoblast proliferation is coordinated with differentiation and 
what factors determine whether cytotrophoblast cells divide or differentiate and 
syncytialize. A few studies localized cell cycle regulators that are specifically expressed 
during key transitions and phases [81-83]. 
The hypothesis that the coordinated expression of cell cycle progression and inhibition 
factors will determine whether cytotrophoblasts proliferate or undergo cell cycle arrest or 
cell cycle exit allowing subsequent differentiation was tested by our team. The cell cycle 
promoters cyclin A, cyclin B1, proliferating cell nuclear antigen (PCNA), Ki67 and the cell 
cycle inhibitors p21, p27 and p57 were immunolocalized in tissue sections of first trimester 
pregnancies (weeks 6 and 9-12). Villous cytotrophoblasts were immunolabelled for Ki67 and 
cyclin A but only few were stained with anti-cyclin B1. The syncytiotrophoblast was devoid 
of immunoreactivity for any of the cell cycle progression factors. It expressed especially p21, 
whereas p27 and p57 were predominantly found in villous cytotrophoblasts. PCNA, Ki67, 
cyclin A and cyclin B1 were immunolocalized in proximal and distal EVTs of anchoring villi 
and in EVT which had invaded the upper decidual segments. All EVTs strongly expressed 
p27 and p57, but not p21. These data clearly suggest different functions for p21, p27 and p57 
in placental development with distinct roles for p21 and p57 in syncytiotrophoblast and EVT 
differentiation, respectively. p27 appears to be involved in both the processes. The results 
may also challenge the concept of differential mitotic activity in the proximal and distal 
parts of the first trimester cytotrophoblast cell column, but more functional studies are 
clearly needed. The presence of p27 and p57 in EVT cells, which invade the deciduas deeply, 
may account for the loss of mitogenic potential of these cells [84]. 
Although the architecture of the human and rodent placentas differs, their anatomical structures 
and molecular mechanisms have been compared [85, 86] and analogies drawn between the 
various cell types; furthermore, the molecular mechanisms of placental development are thought 
to be very similar between the two species. Thus, the rodent placenta is increasingly used as a 
model to study mechanisms underlying placental development [85, 87]. 
 
Figure 1. Schematic representation of cell cycle related proteins in rat placenta of our study [88]. 
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We have been used to localize G1 cyclins (D1, D3, E), which are major determinants of 
proliferation, Cip/Kip inhibitors, p53 as a master regulator and proliferating cell nuclear 
antigen in all cell types of the rat term placenta. Schematic representation of cell cycle 
related proteins studied is showed in Figure 1. The proportion of each cell type 
immunolabeled was counted. Cyclin D1 and cyclin D3 were present mostly in cells of the 
fetal aspect of the placenta, whereas the G1/S cyclin E was present only in the spongio- and 
labyrinthine trophoblast populations. Among the Cip/Kip inhibitors, p21 was present only 
in cells of the fetal aspect whereas p27 and p57 were found in all cell types studied. p53 was 
only found in a small proportion of cells with no co-localization of p53 and p21 [88]. 
Schematic representation of our immunohistochemistry results in the rat placenta is showed 
in Figure 2. The data suggest that the cells of the fetal side of the rat placenta still have some 
proliferation potential which is kept in check by expression of the Cip/Kip cell cycle 
inhibitors, whereas cells of the maternal aspect have lost this potential. Apoptosis is only 
marginal in the term rat placenta. In conclusion, proliferation and apoptosis in rat placental 
cells appears controlled mostly by the Cip/Kip inhibitors in late pregnancy. It is still not 
known how coordination mechanisms of proliferation and differentiation are influenced by 
glucocorticoid induced IUGR in the placenta. 
 
Ch: Chorion, LZ: Labyrinth Zone (fetal placenta), JZ: Junctional Zone (maternal placenta) [88]. 
Figure 2. Schematic representation of our immunohistochemistry results in the rat placenta. 
We aimed to investigate the effects of maternally administered synthetic glucocorticoid Dex 
on cell proliferation, cell cycle arrest or apoptosis of placental development. We investigated 
the spatial and temporal immunolocalization of PCNA, Ki67, p27 and p57 in normal and 
Dex-induced IUGR placental development in pregnant rats. PCNA immunolabeling intensity 
in placentas of the control group was statistically significantly higher than that in the Dex-
induced IUGR group placentas on all days in junctional and labyrinth zones (JZ and LZ, 
respectively). We observed decreased Ki67 staining intensity in the labyrinth trophoblasts of 
Dex-induced IUGR placentas compared to controls on day 21. Ki67 immunolabeling intensity 
was higher in the control group than that in the IUGR group placentas on all days in both 
zones except for day 21 in the junctional zone. These differences were statistically significant 
on days 15, 17 and 19 in the junctional zone and on days 13, 15, 17 and 21 in the labyrinth 
zone. Ki67 staining intensity decreased gradually after day 15 in both zones of control and 
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IUGR placentas. Ki67 immunostaining intensities were stronger in the labyrinth zone 
compared to the junctional zone in both groups. Moreover, after day 17, scarcely any Ki67 
immunostaining was obtained in the IUGR placentas in the junctional zone. We found 
stronger p27 immunolabeling intensity in Dex-induced IUGR placentas when compared to 
control placentas in both junctional and labyrinth zones for all gestational days (Table 1) [89]. 
In accordance with this, in another study, it was observed that in the Dex-induced human 
choriocarcinoma JEG-3 cells p27 mRNAs were upregulated [90]. We observed that p57 
immunostaining intensities in Dex-induced IUGR placentas were stronger compared to 
controls in both zones for all gestational days. We found that Dex-induction results in p57 
upregulation in rat placental development [89]. In contrast to our results, p57 was not 
expressed in Dex-induced JEG-3 cells [90]. In another study, we wanted to determine the 
Ser/Thr protein kinase Akt and a MAPK (Mitogen-Activated Protein Kinase) ERK1/2 related 
proliferation and apoptosis mechanisms are influenced by Dex-induced IUGR placentas. 
Thus, we investigated the expression levels and spatio-temporal immunolocalization of Akt, 
p-Akt, ERK1/2 and p-ERK1/2 proteins in normal and Dex treated placental development of 
rats. We found that maternal Dex treatment led to a decrease in ERK1/2 and Akt activation 
during rat placental development together with placental and fetal weight loss. Akt 
activation was significant at junctional zones of the rat placenta, especially at 
spongiotrophoblast cells and giant cells, and reduced after dexamethasone treatment. On the 
other hand, ERK1/2 activation was seen in both junctional and labyrinth zones of the rat 
placentas and was weaker in labyrinth zones of IUGR group placentas. The decrease in 
ERK1/2 and Akt activation may result in cell survival inhibition or apoptosis stimulation. 
Consequently, Dex induced placental and embryonal developmental abnormalities could be 
associated with reduction of Akt and ERK1/2 activation [91]. In another study, decreased 
levels of placental Akt phosphorylation was observed after in utero exposure to Dex [92]. 
Antenatal Dex use is associated with reduction in fetal and placental weight with 
morphological changes in the placenta. Dex-treated mouse placentas showed swollen 
trophoblast cells in both the junctional and labyrinth zones and increased apoptosis of 
trophoblast cells in the junctional zone. Moreover, Dex-treated placentas were hydropic, 
friable and pale [58]. Increasing antenatal corticosteroid exposure was associated with 
villous fibrosis, stromal mineralization, and less frequent villous infarction [93]. In addition, 
treatment with Dex prevented the normal rise in VEGF expression and the associated 
increase in labyrinthine vascularity over the final third of pregnancy. Therefore, Dex 
appears to reduce labyrinth zone growth by preventing the normal development of the fetal 
vasculature within the labyrinth zone [59]. Moreover, microarray analysis showed that Dex 
caused a decrease in expression of genes involved in cell division such as cyclins A2, B1, D2, 
CDK 2, CDK 4 and M-phase protein kinase along with growth-promoting genes such as 
epidermal growth factor receptor, bone morphogenetic protein 4 and insulin-like growth 
factor-binding protein 3 [58]. In addition, 3H-thymidine incorporation assay revealed that 
proliferation of trophoblast cell lines JEG-3 and HTR-8/SV neo and human first-trimester 
primary trophoblasts was time- and dose-dependently inhibited by glucocorticoids [94]. 
Impaired growth in Dex-treated placentas was also characterized by decreased expression of 
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both prolactin-like protein-B and insulin-like growth factor (IGF)-II, particularly in the 
junctional zone of the rat placenta [92]. Dex-treatment increased apoptosis of trophoblast 
cells in mouse and rat placentas. Dex-induced trophoblast apoptosis was mediated through 
activation of caspases 1 and 3 [58, 95]. Apoptosis was also induced in primary cultures of 
third trimester human decidual cells when treated with cortisol, cortisone, or 
dexamethasone [34]. Likewise, Dex was shown to induce both apoptosis and necrosis in 
primary cultures of term human placental trophoblast, in an in vitro model of 
syncytialization and in the SGH-PL4 cell line derived from human extravillous trophoblasts 
by measuring the cytokines TNF-alpha and IFN-gamma using the TUNEL technique, 
Annexin V binding, fluorescence microscopy and ATP/ADP measurements [96]. In another 
study, using a human in vitro term placental explant model, Dex treatment was shown to be 
associated with morphological (accelerated apical microvilli formation, nuclear maturation,  
 
Gestational 
days 
Junctional 
Zone 
Labyrinth 
Zone 
Cell cycle 
protein 
13  
PCNA 
15  
17   
19  
21  
    
13  
Ki67 
15  
17  
19  
21  
    
13   
p27 
15  
17  
19  
21  
    
13  
p57 
15  
17  
19  
21   
Table 1. Immunolabeling intensity changes of PCNA, Ki67, p27 and p57 in the junctional and labyrinth 
zones of placentas of the IUGR group rat placentas compared to control of given gestational day 
(p=<0.05). −, statistically significantly unchanged; , statistically significantly increased; , statistically 
significantly decreased. 
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and increased cell organelle number) and functional (elevated hCG secretion, increased 11β-
HSD2 mRNA expression and reduced cytotrophoblast proliferation markers) of 
syncytiotrophoblast differentiation. These findings suggest that Dex stimulates 
syncytiotrophoblast differentiation and maturation [57]. In another study, BeWo and JEG-3 
choriocarcinoma cell lines used as models for human trophoblast were cultured with another 
synthetic glucocorticoid triamcinolone acetonide (TA). TA altered the number of viable and 
dead cells as well as cyclin B1 expression levels shown by Western blotting and to a lesser 
extent, invasion of BeWo and JEG-3 cell lines determined by Matrigel invasion assay and by 
measuring the secretion (ELISA) of matrix-metalloproteinases (MMP-2, MMP-9) [97].  
3. The effects of glucocorticoids on fetal and placental angiogenesis 
mechanisms 
Angiogenesis is a complex process that may be initiated by a large number of stimuli and 
that is performed through multiple biologic pathways and a variety of molecules. With the 
increased understanding of angiogenesis, it has become clear that many of its pathways are 
parallel and redundant, greatly complicating efforts to interrupt the process. The disruption 
of one pathway most likely does not abolish completely the formation of new blood vessels, 
which may explain the less than perfect clinical results achieved when treating neovascular 
processes with currently available regimens. Combination therapies and drugs that target 
more than one pathway have become more popular and intensively explored. 
Angiogenesis is required for the cyclic processes of endometrial growth, breakdown, and 
repair during the menstrual cycle, and it provides a richly vascularized tissue receptive for 
implantation and placentation [98]. Besides, the formation of new blood vessels is essential 
for organogenesis and successful embryonic and fetal development. 
For many years glucocorticoids have been used in pregnant women for several reasons such 
as risk of premature deliveries or treatment of a variety of medical disorders like bronchial 
asthma, systemic lupus erythematosous etc.. The dosages and types of glucocorticoids 
changes depending on the severity of the symptoms and treatment procedure [99].   
It is reviewed by Hadoka et al. [100] that endogenous GCs contribute to physiological 
angiogenesis mechanisms by regulating the new vessel formation processes. Endothelial 
cells are seem to be a target of glucocorticoid effect as they both express glucocorticoid and 
mineralocorticoid receptors [101, 102]. But overexposure to glucocorticoids during 
pregnancy has adverse effects on placental angiogenesis mechanisms. Therefore these 
steroids should be carefully used in pregnancy.  
Hewitt et al. [59] investigated the impact of increased glucocorticoid exposure on the spatial 
and temporal expression of the endothelial cell-specific mitogen; VEGF and associated 
placental vascularization over the final third of rat pregnancy. They showed that treatment 
with dexamethasone prevented the normal rise in VEGF expression as a LZ specific manner. 
Their data suggest that glucocorticoid induced restriction of fetal and placental growth is 
mediated, in part, via inhibition of placental VEGF expression and associated reduction in 
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placental vascularization. Therefore, dexamethasone appears to reduce LZ growth by 
preventing the normal development of the fetal vasculature within the LZ.  
As it is mentioned in the study above, GCs have adverse effect on placental 
angiogenesis mechanisms. This effect would be related with both angiogenic activity of 
the endothelial cells or maybe related with proliferation or cell survival processes. It 
was reported in a previous study that GCs inhibit tube formation of cultured 
endothelial cells [103] but the molecular mechanisms underlying this effect hasn’t been 
clearly understood [104].  
Recently, Logie et al. [105] reported that GCs do not affect the endothelial cell viability or 
proliferation but tube formation capacity.  This investigation addressed the hypothesis that 
the potent antiangiogenic action of glucocorticoids is due to prevention of tube formation by 
endothelial cells. Cultured human umbilical vein endothelial cells (HUVEC) and aortic 
endothelial cells (HAoEC) were used to determine the influence of glucocorticoids on tube-
like structure (TLS) formation, and on cellular proliferation, viability and migration. 
Dexamethasone or cortisol (at physiological concentrations) inhibited both basal and 
prostaglandinF-2α -induced and VEGF stimulated TLS formation in endothelial cells 
cultured on Matrigel, effects which were blocked with the glucocorticoid receptor antagonist 
RU38486. Glucocorticoids had no effect on endothelial cell viability, migration or 
proliferation. Time-lapse imaging showed that cortisol blocked VEGF-stimulated 
cytoskeletal reorganization and initialization of tube formation. Exposure to glucocorticoids 
reduced the formation of cell-cell contacts rather than increasing degradation of existing 
tubes. They concluded that glucocorticoids interact directly with glucocorticoid receptors on 
vascular endothelial cells (ECs) to inhibit TLS formation. This action, which was conserved 
in ECs from two distinct vascular territories, was due to alterations in cell morphology 
rather than inhibition of EC viability, migration or proliferation. These findings provide 
important insights into the anti angiogenic action of endogenous glucocorticoids in health 
and disease [105]. 
According to the results of an ongoing study of us, Triamcinolone treatment decreased 
VEGF expression in HUVECs. In this study, we tested the hypothesis that IUGR could be 
observed in fetuses as a result of insufficient nutrient transport depending on the 
glucocorticoid effect on placental angiogenesis mechanism that leads to inadequate vessel 
development. HUVECs were cultured at different concentrations (0.5, 5, 50 µmol/L) of the 
synthetic glucocorticoid triamnicinolone acetonide for 48 and 72 hours. After culture, RT-
PCR, ELISA, Western blot and Matrigel experiments were performed. On the other hand, 
dexamethasone was injected to rats during gestation. Placenta and blood samples were 
taken from rats on gestational days 14, 16, 18 and 20.  RT-PCR and Western blot analyses 
were performed on placentas while ELISA test was applied to sera and HUVEC culture 
media. We found that in HUVECs; VEGF, VEGFR1, VEGFR2, Placental Growth Factor 
(PIGF) and Fibroblast Growth Factor (FGF) gene levels on 48 and 72 hours decreased in 50 
mM TA groups compared to control. VEGF protein amount on 48 and 72 hours decreased 
in TA groups compared to control. VEGFR1 protein quantity decreased and VEGFR2 
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protein quantity increased in a dose- and time-dependent manner. According to ELISA 
results, VEGFR1 secreted by HUVEC cells decreased while VEGFR2 and FGF increased. In 
Matrigel experiments, decreased vessel tube structures were created by HUVEC cells 
exposed for 72 hours to 50 mM TA. The amount of VEGF in Dex treated rat sera 
statistically significantly decreased on days 14, 16 and 20, while there is no difference on 
day 18 compared to control. VEGF protein amount showed a decrease in all gestational 
days of IUGR group compared to control in rat placentas. VEGFR1 decreased in advancing 
pregnancy days of control group while increased in parallel to pregnancy days of IUGR 
group. VEGF and  VEGFR1 gene level was lower at term rat placentas compared to control 
group at gestational day 20. In conclusion our results showed that glucocorticoids had a 
negative effect on angiogenesis mechanism  (Figure 3) via altering the angiogenesis related 
protein and gene expression, and tube formation capacity and angiogenesis related 
proteins in sera  (A.Ozmen, G.Unek, D.K. Korgun, I.Mendilcioğlu and E.T.Korgun 
unpublished). 
 
Figure 3. A possible model for glucocorticoid effect on endothelial cells. In physiological conditions; in 
the case of moderate GC concentrations (left picture), vascular homeostasis is tightly regulated.  VEGF, 
VEGFR1&R2 expression, angiogenic cytokine production, endothelial cell migration, blood flow 
velocity etc… is maintained in a balance in functional endothelial cells. But when GC concentration is 
increased (right picture), endothelial cell are subjected to excess GC. And this GC overexposure results 
with endothelial dysfunction by downregulating VEGF and VEGFR1 expression, upregulating VEGFR2 
expression, altering angiogenic cytokine production and by inhibiting endothelial cell migration etc… 
(vWF: Von Willebrand Factor) 
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In another study of ours, we investigated the effects of glucocorticoids on rat placental 
development depending on the PI3K/Akt and MAPK-ERK1/2 pathways [91]. It was 
observed that, the IUGR group had significantly smaller embryos on day 20 of gestation 
and had smaller placentas on day 14, 16, 18 and 20 compared with control.  Maternal 
dexamethasone treatment led to a significant decrease in Akt activation on day 16, 18, and 
20. Total Akt protein expression was not significantly affected by the treatment. There was 
a significant decrease in ERK1/2 activation on day 18 in IUGR group; on the other hand 
there was a significant increase on day 16. Total ERK1/2 protein expression didn’t show 
any significant difference between groups. We observed that phospho-Akt 
immunolabelings were remarkable in junctional zone in control groups and weaker in 
IUGR groups. Phospho-ERK1/2 immunolabelings were considerable in the junctional and 
labyrinth zones in the control groups and weaker in IUGR groups. We found that ERK1/2 
activity was decreased in the dexamethasone treated IUGR groups. This decrease was 
especially seen in the LZ of the rat placenta. Concerning the importance of Erk1/2 on 
placental vasculature development [106-109], it could be said that the decrease in ERK1/2 
activity might be related with vascular failure and this could result with abnormal 
placental development. Besides it is mentioned in the literature that the PI3K/Akt 
pathway modulates the expression of some angiogenic factors such as nitric oxide and 
angiopoietins. Numerous inhibitors targeting the PI3K/Akt pathway have been 
developed, and these agents have been shown to decrease VEGF secretion and 
angiogenesis. [110]. Therefore, dexamethasone induced decreased Akt phosphorylation 
may negatively affect the placental angiogenesis mechanisms. There are some other 
studies [111, 112] mentioning the effect of GCs on fetal/placental vasculature during 
pregnancy. These studies report that GCs alter the physiological condition of the 
vasculature and leads pathological conditions. Aida et al. [111] determined a significant 
depression of total placental eNOS protein measured by ELISA (betamethasone treated vs 
control) and immunohistochemistry in both syncytiotrophoblast and vascular 
endothelium. In conclusion, maternally administered betamethasone produces a 
consistent decrease in several indices of placental eNOS function that may play a role in 
the altered cardiovascular dynamics and fetal growth retardation produced by 
betamethasone administration in late pregnancy.   
Angiogenesis is tightly regulated by hormones.  Hormones regulate blood vessel growth 
by controlling the production of local chemical mediators, often other hormones, but also 
growth factors, cytokines, enzymes, receptors, adhesion molecules, and metabolic factors. 
As mentioned above, GCs may show their effects directly on endothelial cells or indirectly 
for example by altering cytokine production that may affect placental vasculature. Xu et al. 
2005, [9] studied the effects of GCs on placental cytokine production. Villous explants were 
cultured with increasing concentrations of glucocorticoids (betamethasone and methyl-
prednisolone, 0.0025 mM, 0.25 mM and 25 mM). The dose effect of glucocorticoids on 
cytokine (TNF-α, IL-6 and IL-10) production was examined using ELISA. There was a 
stepwise reduction of TNF-α and IL-6 with increasing doses of betamethasone and methyl-
prednisolone from placentas of women with preeclampsia and normal pregnancy. 
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However, IL-10 was not altered in conditioned medium by increasing doses of 
glucocorticoids. In pregnancy, TNF-α can cause direct damage to endothelial cells, increase 
endothelial cell permeability, up-regulate endothelial adhesion molecules (ICAM-1, 
VCAM-1, E-Selectin) and promote vasoconstriction, all of which are identified in the 
pathogenesis of preeclampsia [113]. IL-10 is an immunosuppressive Th2-type cytokine 
which is produced by immune cells including T-cells, monocytes, macrophages, 
granulocytes and NK cells and also trophoblasts. IL-10 has been also shown to be a potent 
inhibitor of Th1 cell proliferation and the production of Th1-type cytokines such as TNF-α 
[114].  
To observe the influence of maternal betamethasone administration for fetal lung 
maturation on the arterial, venous and intracardiac blood flow of the fetus and the uterine 
arteries; twenty-seven women with singleton pregnancies were examined before the first, 
and 30 min and 8, 24, 48 and 72 h after the second of two single doses of 8 mg of 
betamethasone. The blood flow velocity waveforms of the umbilical artery (UA), the middle 
cerebral artery, the uterine arteries, the ductus venosus, the inferior vena cava and the right 
hepatic vein, the pulmonary trunk, the ductus arteriosus and the right and left 
intraventricular inflow of the heart was recorded. The resistance index of the UA showed a 
significant transient decrease 30 min after the second betamethasone dose. The peak systolic 
velocity of the ductus arteriosus increased significantly 30 min after the 2nd dose and then 
returned to non-significant values. No significant change was observed in any of the other 
vessels. So it could be said that Betamethasone causes short-term changes in fetal blood 
flow. However, this effect seems to be mild and reversible and does not appear to 
contraindicate the use of corticosteroids to promote fetal lung maturation [115]. Therefore, it 
could be mentioned that long term dexamethasone usage my result with decreased maternal 
blood velocity which would negatively affect angiogenesis mechanisms as maternal blood 
itself contains angiogenesis related proteins. 
 It is reviewed by Oliver et al. [116] that corticosteroids are believed to act at multiple levels 
of angiogenesis by regulating growth factors, proteases, and blood cell behavior, and have 
shown significant promise in clinical studies of neovascularization secondary to diabetes, 
age-related macular degeneration (AMD), and ocular histoplasmosis syndrome [117-121]. 
Angiostatic steroids have been proposed to inhibit angiogenesis by altering the capillary 
basement membrane composition, suppressing its dissolution, and inhibiting endothelial 
cell migration, in addition to their capacity of regulating the participation of inflammatory 
cells in the neovascular process [122-124]. There is a growing body of evidence that reports 
inhibitive effects of glucocorticoids on angiogenesis mechanisms [105, 125-128] but there is 
limited data about the impact of glucocorticoids on placental angiogenesis mechanisms. 
Glucocorticoid-mediated inhibition of angiogenesis is important in physiology, 
pathophysiology and therapy. However, the mechanisms through which glucocorticoids 
inhibit growth of new blood vessels have not been established. Over-exposure to GCs may 
alter intracellular signaling pathways such as MAPK/ERK1/2 and PI3K/Akt with a 
processes mediated by GR and finally expression of angiogenic proteins could be altered 
(Figure 4). 
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Figure 4. Glucocorticoids might show their effects on angiogenesis mechanisms by altering intracellular 
signal transduction pathways. GCs affect cellular processes via binding Glucocorticoid receptor. MAPK 
and PI3K/Akt (by phosphorylation of several downstream molecules; yellow dots in the picture) 
pathways mediate GC action on placental angiogenesis mechanisms like VEGF, VEGFR1&2 expression 
and endothelial cell cytoskeleton organization etc… (GC; Glucocorticoid, GR; Glucocorticoid Receptor) 
4. The effects of glucocorticoids on placental glucose transporters 
The Glut protein family belongs to the Major Facilitator Superfamily (MFS) of membrane 
transporters [129]. Most Glut proteins catalyze the facilitative (energy-independent) 
bidirectional transfer of their substrates across membranes. Up to now, 14 functional 
mammalian-facilitated hexose carriers (GLUTs) have been characterized by molecular 
cloning [130]. The Glut family members can be grouped into three (Class I, Class II and 
Class III) different classes based on their sequence similarities [131]. The isoforms GLUT1, 3 
and 4 are included in Class I and represent high-affinity transport facilitators.  
The existence of glucose transporters in the placenta have been known for many years. 
GLUT1 protein is present in placental endothelial cells  [132, 133]  and in the basal [132], or 
microvillous membranes of the syncytiotrophoblast  [133-135]. GLUT3 mRNA is distributed 
throughout the cells of villous tissue; GLUT3 protein appears to be expressed only in the 
vascular endothelium and, is not expressed in the syncytiotrophoblast layer of the placenta. 
A strong GLUT4 signal was observed in intravillous stromal cells, appearing to co-localize 
with insulin receptors [136], a discovery which complements the observation of GLUT4 in 
fibroblasts from amnion and chorion [137]. 
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GLUT proteins’ cell surface expression level, greatly influences the rate of glucose uptake 
into the cells [131]. Uptake of glucose by the placenta is facilitated primarily by GLUT1 and 
in part by GLUT3 transporters [133, 138-140]. A possible major glucose transfer mechanism 
in the human placental villi may be depicted as follows. Glucose in the maternal 
bloodstream passes the apical microvillous plasma membrane of syncytiotrophoblast cells 
by means of GLUT1. Glucose moves through the cytoplasm of the syncytiotrophoblast by 
simple diffusion and leaves the cytoplasm via GLUT1 in the basal plasma membrane. 
GLUT1 and GLUT3 proteins contribute to the uptake of glucose by placental endothelial 
cells, as well as facilitate the transfer of glucose into and out of the fetal blood vessels in the 
villous core [133, 138-140]. About 25% of glucose entering the placenta is metabolized within 
this tissue; the majority of glucose is passed to the fetus through placental endothelial cells 
[141]. 
Efficient placental (maternal to fetal) transport of glucose is crucial to sustain the normal 
development and survival of the fetus in utero because its own glucose production is 
minimal [142]. The factors regulating transplacental glucose transfer are largely 
unknown.  
In our recent study [143], we showed that Triamcinolone administration at doses of 0.5, 5 
and 50µmol/L, led to a significant up-regulation of placental GLUT1 and GLUT3 transcripts 
and protein levels in Human Placental Endothelial Cells (HPECs). After several passages, 
the endothelial cells were cultured in the presence or absence (controls) of 0.5, 5 and 
50µmol/L of TA. The lower (0.5 mmol) dose is a concentration in the lower range of doses 
generally used in previous cell culture studies [7] and considered comparable to the doses 
used to promote lung maturation in rats [144]. Other doses (5 and 50 mmol) were used to 
investigate the potentially detrimental effects of glucocorticoid excess. The highest TA dose 
administered to the endothelial cell cultures corresponds to the TA concentration in blood 
resulting after intravenous injection of a dose recommended by the manufacturers for 
therapy in humans. Our Western blot results showed that GC overexposure significantly 
increased placental GLUT1 and GLUT3 protein levels in all experimental groups of HPECs. 
RT-PCR analysis of placental GLUT expressions indicated that both GLUT1 and GLUT3 
mRNA levels were affected by the GC induction. It was supposed that GCs caused an 
increase in placental GLUT proteins and mRNA expression. 
The human placenta is a GC responsive organ consisting of multiple cell types including 
endothelial cells, fibroblasts and trophoblasts that demonstrate changes in gene 
expression after hormone treatment. However, little is known about the relative 
expression or activity of the Glucocorticoid Receptor among the various placental cell 
types. Previous studies have documented that placental endothelial cells expressed GR 
and Mineralocorticoid Receptor (MR) [101, 102] but the GR regulation of glucose transport 
have not been studied. We found that GR mRNA and protein expression down-regulated 
after 24-h cell culture of HPECs. Our results suggest that GC-mediated down-regulation 
of GR levels occurs through changes in protein and mRNA stability in HPECs after TA 
treatment. The data from the cell culture strengthens the hypothesis that increased GC 
levels specifically modulate GLUT expression via the GR. 
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Collectively, we conclude that TA is a potent regulator of HPECs’ GLUT1 and GLUT3 
expression (Figure 5). This effect is mediated by GR. We speculate that GC-induced up-
regulation of the placental glucose transporter systems contributes to the retarded fetal and 
placental growth observed with GC treatment.  
Similarly in a previous study [18], it is reported that exposure to excess glucocorticoids from 
day 15 of gestation modified rodent placental glucose transporter protein expression at day 
21 of gestation in a concentration-dependent manner.  
Dexamethasone treatment from day 15 to day 21 of pregnancy led to fetal 
hypoglycaemia. GLUT1 and GLUT3 protein expression were detectable in the rat 
placenta during late gestation, and dexamethasone treatment from day 15 to day 21 of 
pregnancy significantly decreased placental weight and up-regulated the placental 
protein expression of both glucose transporters during late gestation in a dose-
dependent manner.  
Dexamethasone administration at the lower dose (100µg/kg) led to modest up-regulation of 
placental GLUT1 protein expression, in the absence of any significant change in the protein 
expression of GLUT3. Dexamethasone at the higher dose (200µg/kg) led to significant up-
regulation of the placental expression of both GLUT1 and GLUT3 in rats, with a slightly 
more marked effect on GLUT3 [18]. It is concluded that, depending on the dose 
administered, either maturational glucose transporter isoform switching might be 
accelerated by dexamethasone treatment during late pregnancy or, at a higher dose, 
placental glucose transporter expression would be down-regulated. 
In another study of ours, the glucocorticoid effect on the glucose transporters in the 
diabetic rat placenta was questioned.  It was hypothesized that GCs regulate placental 
glucose transport in many cell types and tissues and depending on this hypothesis the 
relationship between glucose transport and the glucocorticoid metabolism in rat placental 
development of normal and diabetic pregnancy was investigated. The 
immunohistochemical results indicated that GR and GLUT1 are expressed ubiquitously in 
the trophoblast and endothelial cells of the labyrinthine zone. Amounts of GR and GLUT1 
proteins increased towards the end of gestation both in the control and the diabetic 
placenta. However, at days 17 and 19 of gestation, only the placental GR protein was 
significantly increased in the streptozotocin-induced diabetic rats compared to control rats. 
It is mentioned in this study that there might be a relationship between GR and GLUT1 
expressions at the cellular level. GLUT1 does not play a pivotal role in diabetic 
pregnancies. However, placental growth abnormalities during diabetic pregnancy may be 
related with the amount of GR [145].   
It was previously reported by Hahn et al. for the first time, that both GLUT1 and GLUT3 
transcripts and protein were significantly down-regulated in isolated human trophoblast 
cells and in rat placentas by GCs, suggesting regulation at the transcriptional level [7]. 
Hyperglycemia is one of the well known systemic effects following GC treatment. Thus, 
elevated glucose concentrations might have affected placental GLUT expression [146]. 
However, in the rat model, a single injection of TA resulted in only short term 
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hyperglycemia, followed by hypoglycemia. This hypoglycemia may be the reason for the 
smaller fetuses and placentas as well as for the markedly reduced weight gain of TA-
treated rats during gestational days 16 and 21.The human trophoblast cells were cultured 
under physiological glucose concentrations, yet their GLUTs were down-regulated similar 
to those in TA-treated rats. Collectively, the investigators concluded that the synthetic GC 
Triamcinolone is a potent regulator of human and rodent placental GLUT1 and GLUT3 
expression. This effect is mediated by the GR. They speculate that GC-induced down-
regulation of the placental glucose transporter systems contributes to the retarded fetal 
and placental growth observed with GC treatment. This would represent a pathogenetic 
mechanism different from that leading to intrauterine growth retardation in the absence 
of GC treatment, in which trophoblast GLUT1 is not altered [134]. However, it is difficult 
to determine the cause and effect relationships, and the growth restriction could occur 
first, followed by an appropriate down-regulation of the transporters so as to match fetal 
size. 
Consistent with this study, it was also reported that GLUT1 and GLUT3 mRNA levels were 
decreased in the dexamethasone treated group in the caruncles of the caw placenta [147]. In 
this study, plasma glucose concentrations of cows carrying a somatic cell clone fetus during 
late pregnancy and GLUT mRNA levels at parturition were examined. Parturition was 
induced by using dexamethasone and some other molecules. Cotyledon and caruncle tissues 
were removed just after parturition and were used for mRNA extraction. In the caruncules 
of the Dex induced parturition group GLUT1 and GLUT3 mRNA levels were decreased 
according to the Clone Pregnancy. 
In another rat model, female pregnant rats were subjected to % 50 food restrictions in order 
to investigate the effect of maternal nutrient on placental GLUTs. In this model fetuses were 
overexposured to glucocorticoids as maternal protein restriction induces it. At day 21 of 
pregnancy plasma corticosterone levels were increased. Correspondingly, placental GLUT3 
protein was decreased, GLUT1 and GLUT4 protein levels were not affected by maternal 
feeding regimen and therefore enhanced corticosterone level [148]. 
Besides placenta, GCs affect glucose transport in a variety of peripheral tissues, such as 
skeletal muscle, adipocytes, and endothelial cells [149-160]. High affinity low capacity GRs 
have been identified in the placenta of various species, including man, rat, and mouse [17, 
35, 161, 162]. This would have important clinical implications, because GC-induced down-
regulation of the placental glucose transport system(s) may contribute to the deleterious 
side-effects of GC treatment during pregnancy, such as the higher incidence of growth-
retarded fetuses [46, 163-165].   
Corticosteroids have also been shown to have major effects on fetal glucose homeostasis 
resulting in long-term persistence of these changes after birth in sheep and rats [166-172]. 
Prenatal corticosteroid exposure of mice resulted in programming of the fetus such that the 
adult progeny exhibited glucose intolerance [170, 171]. In addition, repeated courses of 
maternal corticosteroid administration have been shown to alter fetal glucose homeostasis 
and hepatic enzyme activity in rats [157, 173]. 
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Figure 5. Effect of glucocorticoid overexposure on GLUT1 and GLUT3 expression in placental 
endothelial cells. GCs bind to GR and activate cellular signal transduction pathways. These molecular 
mechanisms remain to be unknown. As a result of GC overexposure GLUT1 and GLUT3 mRNA and 
proteins are increased in placental endothelial cells. Left panel refers possible physiological conditions 
and right panel refers effects of GC overexposure on GLUTs. (GC; Glucocorticoid, GR; Glucocorticoid 
Receptor, GLUT; Glucose Transporter) 
In summary, the effects of glucocorticoids in placental glucose transport mechanisms in not 
fully understood. Further studies are needed to explain this issue. 
5. Conclusion 
Placental and fetal development is effected from glucocorticoids. Physiological 
glucocorticoid concentrations are necessary for healthy implantation, and pregnancy 
processes. On the other hand, glucocorticoid overexposure results with fetal and placental 
defects. Placentas of dexamethasone treated animals are smaller than healthy ones. In IUGR 
group placentas reduced placental proliferation and induced apoptosis seem to be a reason 
for decreased placental weigths. Dexamethasone caused a decrease in expression of genes 
involved in cell division such as cyclins A2, B1, D2, CDK 2, CDK 4 and M-phase protein 
kinase along with growth-promoting genes such as epidermal growth factor receptor. 
Moreover, in IUGR placentas cell cycle promoter proteins PCNA, Ki67 is decreased and cell 
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cycle inhibitor proteins p27 and 57 are increased. Altered MAPK and Akt pathways are also 
unfavorably affected from glucocorticoid treatment. Decreased Akt and MAPK activations 
would result with reduced proliferation and/or induced apoptosis and reduced 
angiogenesis. GCs may affect placental angiogenesis by altering VEGF, VEGFR1 and 
VEGFR2 expression both at protein and gene levels with a direct effect on endothelial cells. 
Besides, without effecting endothelial cell viability and proliferation, GCs may affect 
endothelial cell migration and/or capacity of tube formation. The indirect effects of GCs 
seem to be via altering placental cytokine production processes which have negative effects 
on angiogenesis mechanisms. Another mechanism by which GCs may alter placental 
development is glucose transport mechanisms. It seems that GCs affect Glucose transporters 
via cell type dependent manner. In human endothelial cells GCs will up-regulate GLUT1 
and GLUT3 expression but in trophoblast cells GCs adversely down regulates GLUT1 and 
GLUT3 expression in vitro. 
In summary glucocorticoid overexposure may alter fetal development by altering, in part, 
placental development and function. It is clearly reviewed that placental development, 
proliferation, angiogenesis and glucose transport mechanisms are negatively affected from 
excess maternal glucocorticoid.  
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